DURHAM, N.C., United States and BEIJING, China – May 27, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced its participation in the following conference in June 2022. Details of the conference and management presentations are as follows:

Citi 3^rd Pan-Asia Regional Investor Conference （Virtual Meeting）
Investor Meetings: June 8-10, 2022
Participants: Management team and IR
For more information, please contact your Citi representative.

Credit Suisse 2022 Asia Healthcare Corporate Day （Virtual Meeting）
Investor Meetings: June 14-16, 2022
Participants: Management team and IR
For more information, please contact your Credit Suisse representative.

Goldman Sachs Hybrid Healthcare Corporate Day （Virtual Meeting）
Investor Meetings: June 20-24, 2022
Participants: Management team and IR
For more information, please contact your Goldman Sachs representative.

H.C. Wainwright 1^st Annual Mental Health Conference （Hybrid Meeting）
Investor Meetings: June 27, 2022
Participants: Management team and IR
Meeting Venue: Lotte New York Palace Hotel
For more information, please contact your H.C. Wainwright representative.

About Brii Bio
Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

Media Inquiry:
media@briibio.com
Summer Li (China)
+86-135-2191-1607
Ben Shannon (U.S.)
+1-919-360-3039

Investor Inquiry:
ir@briibio.com
Chris Fang
+86-139-1692-8049